Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11097MR)

This product GTTS-WQ11097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11097MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6505MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ12728MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ5600MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ10415MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ10925MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ15941MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ10849MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ10998MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW